Q2 2025 · 13F-HR
Octagon Capital Advisors LPholdings as filed
Filed 2025-08-14 · accession 0001839435-25-000007
$455.6M
Reported value
30
Positions
2025-06-30
Period end
The Brief · Octagon Capital Advisors LP · Q2 2025
AI · grounded in 13F
Octagon Capital Advisors LP established a new position in DNTH valued at $43.6M. The fund also initiated new stakes in AVBP for $42.4M and VRNA for $31.9M. Additional new positions include TSHA at $29.1M and SPRY at $23.6M. The fund ended the period with 30 positions and total AUM of $455.6M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $43.6M | 9.57% | 2,341,667 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $42.4M | 9.30% | 1,946,054 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $31.9M | 7.00% | 337,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $29.1M | 6.38% | 12,592,500 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $23.6M | 5.17% | 1,350,000 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $22.6M | 4.95% | 18,350,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $22.5M | 4.94% | 2,425,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $20.5M | 4.49% | 389,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $20.1M | 4.41% | 3,672,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $19.8M | 4.35% | 2,763,000 | Common | SOLE |
| 002120202 | ATYR | ATYR PHARMA INC | $19.4M | 4.25% | 3,820,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $15.6M | 3.43% | 903,500 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $15.0M | 3.29% | 7,691,334 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $14.5M | 3.18% | 905,000 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $14.4M | 3.16% | 1,273,333 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $13.8M | 3.03% | 2,130,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $13.5M | 2.97% | 1,030,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $11.8M | 2.60% | 672,595 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $11.6M | 2.55% | 266,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $9.7M | 2.13% | 1,267,000 | Common | SOLE |
| 23306J309 | DBVT | DBV TECHNOLOGIES S A | $9.3M | 2.04% | 1,018,021 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $7.7M | 1.69% | 1,115,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $7.0M | 1.53% | 148,000 | Common | SOLE |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $4.8M | 1.05% | 1,000,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $4.5M | 0.99% | 303,000 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $2.7M | 0.58% | 250,000 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $2.2M | 0.48% | 177,667 | Common | SOLE |
| 482929106 | KLRS | KALARIS THERAPEUTICS INC | $961,200 | 0.21% | 360,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $889,000 | 0.20% | 700,000 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $300,518 | 0.07% | 154,112 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.